Will Bristol-Myers Squibb (BMY) succeed in acquiring Celgene (CELG)?

The proposed $74 billion deal is under pressure now that two investments firms are opposing the acquisition. On Wednesday, Wellington Management, the largest Bristol shareholder with 8 percent of its stock, argued the deal asks Bristol stockholders to accept too much risk, is priced “well below” asset value, and “could be more difficult to achieve than depicted” by Bristol management.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Mr Chesney’s comment is a bit off – “The deal shrewdly accounts for Celgene’s principle risks.” Certainty cancels out risk, and since other wags argue that Celgene has been proved to have no principles, that cannot be considered a principal risk.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy